A Clinical Report on Treating 21 Cases of Immune Thrombocytopenia with Modified Spleen-invigorating Decoction
Objective:To discuss the immunological mechanisms of modified spleen-invigorating decoction treatment of immune thrombocytopenic purpura (ITP).Methods:42 out-patients and in-patients with ITP from December 2012 to December 2013 were randomly divided into a control group and a treatment group (N =21).The treatment group was given modified spleen-invigorating decoction.The control group was given prednisone.Comparative study on platelet count (PLT) was made after two months of treatment.Enzyme-linked immunosorbent assay (ELISA) was used to detect the contents of IL-18,IL-18 BP,GP H b/ Ⅲ a before and after the treatment in both groups.Methods:The total effective rate in the treatment group was 90.5％,meanwhile,95.2％ in the control group.Compared the two groups,the differences were not statistically significant (P ＞0.05).Differences of IL-18,IL-18BP and GP Ⅱ b/ma before and after treatment were statistically significant (P ＜0.05).Compared the two groups,differences of IL-18,IL-18BP and GP Ⅱ b/Ⅲa contents were not statistically significant (P ＞ 0.05).Conclusion:The immunological mechanisms of modified spleen-invigorating decoction in the treatment of ITP were probably associated with humoral immunity and cellular immunity.
Immune thrombocytopenic purpuraInterleukin-18 and its binding proteinPlatelet membrane glycoprotein
NETL
NSTL
万方数据
维普
